Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS) — ES-ARMS  

Schizophrenia Clinical Trial

Official title: Phase IV Study of Effects of 'Seroquel-XR' on the Improvement of Neurocognitive Function in People At-risk Mental States(ARMS)

Status Recruiting

Clinical Trial Summary

The primary objective of this study is to assess the effects of 'Seroquel-XR' on the verbal learning ability in people with at-risk mental state (ARMS) over a 12 week period. The verbal learning ability will be indexed by delayed free recall score of CVLT(California Verbal learning Test), a standard neuropsychological verbal memory tests.

The secondary objective is to assess the effects of 'Seroquel-XR' on other cognitive function and psychiatric symptoms including psychotic, anhedonic symptoms, and impulsivity. The cognitive function abilities will be measured by standard neuropsychological tests as follows;

• Working memory: verbal & spatial 2-back test

• Attention: Digit Span, 3-7 CPT(Continuous Performance Test)

• Executive function: WCST (Wisconsin Card Sorting Test)

• Visuo-spatial ability: Rey Complex Figure Task copy

• Visuomotor speed and planning: Trail making test A & B

• Verbal fluency: Controlled Oral Word Association Test(COWAT) The scales of psychiatric symptoms which will be used are as follows;

• Psychotic symptoms: Scales of Prodromal scales (SOPS), Positive and negative syndrome scale (PANSS)

• Anhedonia: Social Anhedonia Scale (SAS), Physical Anhedonia Scale (PAS)

• Social cognition: Ambiguous Intention Hostility Questionnaire (AIHQ)

• Impulsivity: Barrett Impulsivity Scale (BIS)

Clinical Trial Description

n/a

Study Design

Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

• Abnormal Mental State
• Schizophrenia

• NCT number: NCT01250847
• Study type: Interventional
• Source: Severance Hospital
• Contact: Suk Kyoon An, MD, Ph D.
• Phone: +82 17 349 8275
• Email: ansk@yuhs.ac
• Status: Recruiting
• Phase: Phase 4
• Start date: November 2010
• Completion date: October 2012